Javascript must be enabled to continue!
Intermittent Transdermal Nitroglycerin Therapy
View through CrossRef
Background
Intermittent transdermal nitroglycerin therapy is effective in the treatment of stable angina and prevents the development of tolerance. Previous investigations have suggested that removal of nitroglycerin patches may be associated with a decrease in anginal threshold. This study examines the effect of nitroglycerin patch removal on anginal threshold in a group of patients with stable angina.
Methods and Results
Twelve patients with stable angina were enrolled in a randomized, double-blind, placebo-controlled, crossover study. These patients had reproducible treadmill walking times and were taking no other long-acting antianginal medications or vasodilators. They received 0.8 mg/h transdermal nitroglycerin or wore a matching placebo patch for 5 to 7 days and then crossed over to the other treatment arm of the study. Transdermal nitroglycerin was applied at 8:00
pm
and removed at 8:00
am
each day. On the last day of each treatment period, patients underwent treadmill exercise testing at 8:00
am
(before patch removal) and at 2, 4, and 6 hours after patch removal. The primary end point was the treadmill walking time until moderate angina (P2). Other end points included the treadmill walking time until onset of angina (P1), the amount of ST segment depression at P1 and P2, and treadmill walking time until the development of 1 mm ST depression. Heart rate, systolic blood pressure, and the rate-pressure product were determined at rest before exercise and at P1 and P2. At 8:00
am
P1 and P2 were not significantly affected by active nitroglycerin compared with placebo, indicating the development of tolerance. Removal of the active transdermal nitroglycerin patch was associated with a significant decrease in the time to P1 at 2, 4, and 6 hours after patch removal compared with placebo. There was also a decrease in the time to P2 after active patch removal that was statistically significant compared with placebo at 2 and 4 hours and was of borderline significance at 6 hours. There were no differences in heart rate, blood pressure, or amount of ST segment depression at either P1 or P2 after active compared with placebo patch removal.
Conclusions
In patients with stable angina pectoris, intermittent transdermal nitroglycerin therapy is associated with a decrease in anginal threshold for 4 to 6 hours after patch removal. Although the cause of this phenomenon remains uncertain, it may be due to counterregulatory responses that develop during nitroglycerin patch application.
Ovid Technologies (Wolters Kluwer Health)
Title: Intermittent Transdermal Nitroglycerin Therapy
Description:
Background
Intermittent transdermal nitroglycerin therapy is effective in the treatment of stable angina and prevents the development of tolerance.
Previous investigations have suggested that removal of nitroglycerin patches may be associated with a decrease in anginal threshold.
This study examines the effect of nitroglycerin patch removal on anginal threshold in a group of patients with stable angina.
Methods and Results
Twelve patients with stable angina were enrolled in a randomized, double-blind, placebo-controlled, crossover study.
These patients had reproducible treadmill walking times and were taking no other long-acting antianginal medications or vasodilators.
They received 0.
8 mg/h transdermal nitroglycerin or wore a matching placebo patch for 5 to 7 days and then crossed over to the other treatment arm of the study.
Transdermal nitroglycerin was applied at 8:00
pm
and removed at 8:00
am
each day.
On the last day of each treatment period, patients underwent treadmill exercise testing at 8:00
am
(before patch removal) and at 2, 4, and 6 hours after patch removal.
The primary end point was the treadmill walking time until moderate angina (P2).
Other end points included the treadmill walking time until onset of angina (P1), the amount of ST segment depression at P1 and P2, and treadmill walking time until the development of 1 mm ST depression.
Heart rate, systolic blood pressure, and the rate-pressure product were determined at rest before exercise and at P1 and P2.
At 8:00
am
P1 and P2 were not significantly affected by active nitroglycerin compared with placebo, indicating the development of tolerance.
Removal of the active transdermal nitroglycerin patch was associated with a significant decrease in the time to P1 at 2, 4, and 6 hours after patch removal compared with placebo.
There was also a decrease in the time to P2 after active patch removal that was statistically significant compared with placebo at 2 and 4 hours and was of borderline significance at 6 hours.
There were no differences in heart rate, blood pressure, or amount of ST segment depression at either P1 or P2 after active compared with placebo patch removal.
Conclusions
In patients with stable angina pectoris, intermittent transdermal nitroglycerin therapy is associated with a decrease in anginal threshold for 4 to 6 hours after patch removal.
Although the cause of this phenomenon remains uncertain, it may be due to counterregulatory responses that develop during nitroglycerin patch application.
Related Results
Portal hemodynamics during nitroglycerin administration in cirrhotic patients
Portal hemodynamics during nitroglycerin administration in cirrhotic patients
Nitroglycerin is a potent venous dilator and a mild arterial vasodilator that has been shown to improve the hemodynamic response to vasopressin in portal hypertensive patients and ...
Formulation, Development and Characterization of Transdermal Patches of Metformine Hydrochloride as Lοw Dοse Maintenance Therapy
Formulation, Development and Characterization of Transdermal Patches of Metformine Hydrochloride as Lοw Dοse Maintenance Therapy
The οbjective οf the prοpοsed study was tο develοp lοw dοse support treatment οf metformin hydrochloride in diabetic patients. The pοtassium brοmide pellet was mοunted in IR compar...
Optimizing Cardiovascular Performance Following Myocardial Infarction: The Significance of Nitroglycerin in Regulating Blood Flow
Optimizing Cardiovascular Performance Following Myocardial Infarction: The Significance of Nitroglycerin in Regulating Blood Flow
Background & Objectives: Nitroglycerin, a potent vasodilator, is crucial in managing blood flow dynamics in patients recovering from Myocardial Infarction (MI). This research a...
Current Technological Trends in Transdermal Biosensing
Current Technological Trends in Transdermal Biosensing
Transdermal biosensing focuses on the qualitative and quantitative collection and detection of biomarkers on and in the skin layers. In comparison to the blood‐based diagnosis, tra...
Comparison of Intermittent Versus Continuous Phototherapy in Neonatal Hyperbilirubinaemia
Comparison of Intermittent Versus Continuous Phototherapy in Neonatal Hyperbilirubinaemia
Background: Neonatal jaundice is a common condition characterized by elevated bilirubin levels, which, if untreated, can lead to severe complications such as kernicterus. Photother...
Intermittent Fasting in Sickle Cell Disease: Case series and Review of Literature
Intermittent Fasting in Sickle Cell Disease: Case series and Review of Literature
Abstract
Presentation Date: 6/8/2024
Presentation Start Time: 6:00:00 PM
...
Effects of irrigation and nitrogen fertilization on mitigating salt-induced Na+ toxicity and sustaining sea rice growth
Effects of irrigation and nitrogen fertilization on mitigating salt-induced Na+ toxicity and sustaining sea rice growth
Abstract
This study investigated the effects of irrigation and nitrogen (N) fertilization on mitigating salt-induced Na+ toxicity and sustaining sea rice growth for ...
FORMULATION AND EVALUATION OF TRANSDERMAL PATCHES OF PSEUDOEPHEDRINE HCL
FORMULATION AND EVALUATION OF TRANSDERMAL PATCHES OF PSEUDOEPHEDRINE HCL
Objective: This study was conducted to design a transdermal dosage form of pseudoephedrine HCL and to evaluate its release under controlled rates for sustained transdermal delivery...

